Moving on After Breast Cancer: support for breast cancer survivors with depression in Pakistan
Official title: Clinical and Cost-effectiveness of an Integrated Psychosocial Care Plan for Comorbid Depression in Breast Cancer Survivors In Pakistan: A Sequential Multiple Assignment Randomised Trial
Run by Pakistan Institute of Living and Learning · NCT07015944 · Data updated 2026-11-12
This trial will test a three-stage adaptive program to see if it helps breast cancer survivors in Pakistan who have major depression feel better and lowers care costs.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 26376 (estimated) |
| Sponsor | Pakistan Institute of Living and Learning Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Karachi, Sindh) |
| Status | Recruiting |
| Started | June 13, 2025 |
| Main results expected | December 30, 2028 |
| Study ends | December 30, 2028 |
| Registry record updated | March 18, 2026 |
| Trial ID | NCT07015944 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18 or older who are breast cancer survivors who have completed initial treatment and have a PHQ-9 score of 10 or more with a current Major Depressive Episode confirmed by SCID are ideal candidates.
✕Probably not a fit
Patients with severe medical or psychiatric conditions preventing participation (including those with advanced symptomatic metastatic disease requiring daily symptom control), those lacking capacity to consent, or those without current depression are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This large SMART (Sequential, Multiple Assignment, Randomised Trial) will enrol about 26,372 women breast cancer survivors aged 18 and older who completed initial cancer treatment and screen positive for depression (PHQ-9 ≥10) with diagnosis confirmed by SCID. Participants will be recruited from primary care units, outpatient and oncology clinics in public hospitals, and charitable organisations across Pakistan and randomised to a stepped, adaptive intervention pathway versus enhanced usual care. The adaptive pathway uses non-specialist delivered low-intensity guided self-help, a tailored 'Moving on After Breast Cancer (ABC) plus' approach, and standardised antidepressant treatment, with progression determined by response at each stage. Outcomes include clinical depression symptoms and cost-effectiveness of the three-stage program.
Why it matters
Potential benefit: If successful, the program could reduce depressive symptoms and improve daily functioning while providing a scalable, affordable care model for breast cancer survivors in Pakistan.
How similar studies have gone: Task-shared, low-intensity psychological interventions and stepped-care models have shown benefit for depression in LMICs and general medical populations, but large-scale SMART trials specifically for breast cancer survivors in LMICs are novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women * Aged 18 years and above * Diagnosed with breast cancer (any stage) * Completed initial treatment (i.e., surgery and/or radiotherapy or chemotherapy) for breast cancer (even if they are currently on hormonal therapy post-initial treatment) * Total score of 10 or above on the Patient Health Questionnaire (PHQ-9) * Diagnosis of current Major Depressive Episode (MDE) confirmed using the Structured Clinical Interview for DSM-5 (SCID). Exclusion Criteria: * Lacking capacity to provide informed consent, such as those identified by clinicians as having intellectual disabilities, dementia, or severe medical and/or psychiatric illnesses requiring hospitalisation * Unable to engage in assessments or interventions, including those with stage 4 breast cancer experiencing significant symptoms (e.g., metastatic lesions in the lungs, liver, or bones requiring daily treatment for symptomatic relief, such as the daily use of two or more painkillers), which restrict their capacity to participate * Currently receiving psychological therapy or taking antidepressant medications (e.g., SSRIs, SNRIs, or other prescribed antidepressants)
Where it's running
-
Pakistan Institute of Living and Learning
Karachi, Sindh, Pakistan Recruiting
Study contacts
- Principal investigator: Nasim Chaudhry, MD — Pakistan Institute of Living and Learning
- Study coordinator: Tayyeba Kiran, PhD
- Email: tayyaba.kiran@pill.org.pk
- Phone: 0923328262142
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures
This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.
-
Temporally Interfering Electrical Stimulation for Major Depressive Disorder
This study tests whether noninvasive temporally interfering electrical stimulation can help people with major depressive disorder.
-
Affective Cognitive Training for mood disorders and their close relatives
A six-week program combining virtual reality and computer exercises tests whether affective cognitive training helps people with mood disorders and their unaffected first-degree relatives.
-
ALKS 7290 added to antidepressants for adults with major depression
This study tests whether ALKS 7290, taken with current antidepressants, helps adults with major depressive disorder.
-
French Minds: a French, Multimodal Cohort Study of Severe Psychiatric Disorders and Healthy Controls
This study tests whether people with mood, psychotic, or autism disorders can be grouped into more similar subtypes based on social withdrawal and anhedonia, across ages 15 to 60.
-
EEG-Guided TMS for Adults With Depression
This study tests whether delivering intermittent theta burst stimulation (iTBS) timed to brain waves using EEG can improve treatment for adults with major depressive disorder who have not responded to usual antidepressants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.